23andMe™ Launches Web-Based Personal Genome Service™ Outside U.S.
News Jan 23, 2008
23andMe, Inc. has announced that it has begun making its services available to consumers in Canada and 49 European countries. The company, which officially launched in the U.S. on November 16, 2007, helps individuals understand their own genetic information through the latest advances in DNA analysis technologies and web-based interactive tools.
23andMe was recently selected as a 2008 Technology Pioneer by the World Economic Forum and will be participating in the 2008 World Economic Forum Annual Meeting from January 23-28, 2008 in Davos, Switzerland.
Representatives from the company will be available to press and forum attendees at the 23andMe Booth on Wednesday, January 23rd to Saturday, January 26th 2008 from 10.00am – 2.00pm and 5.00pm – 11.00pm CET daily.
The 23andMe™ service enables its customers to:
• Search and explore genes contributing to their personal characteristics, such as lactose intolerance, athletic ability, and food preferences;
• Learn how the latest research studies relate to their genomes;
• Compare their profiles to family and friends who are also 23andMe participants and trace the inheritance of genes associated with specific traits;
• Discover genetic roots and find out where and how their ancestors lived and learn about the prehistoric events they experienced, and;
• Actively participate in a new research approach and contribute to the advancement of the field of genetics.
Linda Avey, co-founder of 23andMe, said, "We are receiving overwhelming interest in our services outside the U.S. and are pleased to now offer them in Canada and Europe. Our web-based service model has made the European and Canadian offering possible, and we hope to continue to expand our global footprint to additional locations in the future.
Ms. Avey continued, "We believe 2008 will be a year in which our understanding of the human genome will increase significantly through international research efforts, and we are eager to continue connecting individuals to this growing knowledge base of genetic information."
“23andMe came together because we believe in empowering individuals by helping them understand their genetic make-up and actively engaging them in the development of new ways to accelerate research,” said Anne Wojcicki, co-founder of 23andMe. “We enter the European and Canadian markets with great momentum and are excited to continue toward our goal of offering our services to the global community.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.